<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02825563</url>
  </required_header>
  <id_info>
    <org_study_id>ALTN-I-05</org_study_id>
    <nct_id>NCT02825563</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients</brief_title>
  <official_title>Phase I Additional Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to further study the pharmacokinetic characteristics of&#xD;
      Anlotinib in Advanced Cancer Patients with High Fat Diet.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">August 15, 2018</completion_date>
  <primary_completion_date type="Actual">August 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of Anlotinib (in whole blood):Peak Plasma Concentration(Cmax)</measure>
    <time_frame>up to 14 Days</time_frame>
    <description>Peak Plasma Concentration(Cmax),Cmax in ng/mL.In the study , full PK profiles will be obtained at H0/H1/H2/H4/H8/H11/H24/H48/H96/H144/H192/H240/H336(H mans Hour).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of Anlotinib (in whole blood):Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>up to 14 Days</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC), AUC in ng.h/mL.In the study , full PK profiles will be obtained at H0/H1/H2/H4/H8/H11/H24/H48/H96/H144/H192/H240/H336(H mans Hour).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Anlotinib (in whole blood):Peak time（Tmax）</measure>
    <time_frame>up to 14 Days</time_frame>
    <description>Peak time（Tmax）,Tmax in h.In the study , full PK profiles will be obtained at H0/H1/H2/H4/H8/H11/H24/H48/H96/H144/H192/H240/H336(H mans Hour).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Anlotinib(In the fasting state)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the fasting state, Anlotinib po only once and after 14 days it could be continued by Qd po.until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anlotinib(In the high fat diet state)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the high fat diet state, Anlotinib po only once and after 14 days it could be continued by Qd po.until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>in the fasting state</description>
    <arm_group_label>Anlotinib(In the fasting state)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>in the high fat diet</description>
    <arm_group_label>Anlotinib(In the high fat diet state)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological documentation of Advanced solid tumors( Non-small Cell Lung Cancer.Soft&#xD;
             Tissue SarcomaMedullary. Thyroid Carcinoma)&#xD;
&#xD;
          -  At least one measurable lesion (by RECIST1.1)&#xD;
&#xD;
          -  Lack of the standard treatment or treatment failure&#xD;
&#xD;
          -  20≤BMI≤25&#xD;
&#xD;
          -  18-70 years,ECOG PS:0-1,Life expectancy of more than 3 months&#xD;
&#xD;
          -  Main organs function is normal&#xD;
&#xD;
          -  Women of childbearing potential should agree to use and utilize an adequate method of&#xD;
             contraception (such as intrauterine device，contraceptive and condom) throughout&#xD;
             treatment and for at least 6 months after study is stopped；the result of serum or&#xD;
             urine pregnancy test should be negative within 7 days prior to study enrollment，and&#xD;
             the patients required to be non-lactating；Man participants should agree to use and&#xD;
             utilize an adequate method of contraception throughout treatment and for at least 6&#xD;
             months after study is stopped&#xD;
&#xD;
          -  Patients should participate in the study voluntarily and sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clear allergies to the study drug or its ingredients&#xD;
&#xD;
          -  Had the disease to affect drug absorption and metabolism&#xD;
&#xD;
          -  Patients with factors that could affect oral medication (such as dysphagia，chronic&#xD;
             diarrhea, intestinal obstruction etc.)&#xD;
&#xD;
          -  Brain metastases patients with symptoms or symptoms controlled &lt; 1 months&#xD;
&#xD;
          -  Used any drugs inhibit or induce hepatic drug metabolic enzymes in 30 days before the&#xD;
             study&#xD;
&#xD;
          -  Patients with drug abuse history and unable to get rid of or Patients with mental&#xD;
             disorders&#xD;
&#xD;
          -  Patients participated in other anticancer drug clinical trials within 4 weeks&#xD;
&#xD;
          -  Patients with concomitant diseases which could seriously endanger their own safety or&#xD;
             could affect completion of the study according to investigators' judgment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 29, 2016</study_first_submitted>
  <study_first_submitted_qc>July 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>May 20, 2019</last_update_submitted>
  <last_update_submitted_qc>May 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

